Substrate specific protein degradation mediated by the ubiquitin (Ub) proteasome system (UPS), is crucial for the proper function of the cell. Proteins are specifically recognized and ubiquitinated by the Ub ligases (E3s), and are then degraded by the proteasome. BTB proteins act as the substrate recognition subunit that recruits their cognate substrates to the Cullin (Cul) 3-based multi-subunit E3s. Recently, it was reported that missense mutations in KLHL7, a BTB-Kelch protein, are related to autosomal dominant Retinitis Pigmentosa (adRP). However, the involvement of KLHL7 in the UPS and the outcome of the adRP causative mutations were unknown. In this study, we show that KLHL7 forms a dimer, assembles with Cul3 through its BTB and BACK domains, and exerts E3 activity. K48-but not K63-linked poly-ubiquitin chain co-localized with KLHL7, which increased upon proteasome inhibition suggesting that KLHL7 mediate protein degradation via UPS. An adRP causative
autophagy-mediated protein degradation (4) .
Other modes of the Ub chain are present in eukaryotic cells (5) , but the functions of each form are yet to be elucidated.
In the ubiquitination reaction, Ub is first activated by the Ub-activating enzyme E1, and then carried by the Ub-conjugating enzyme E2 to the Ub ligase E3, where the Ub is attached onto a lysine residue of the specific substrate of the E3s (1, 2) . The substrate specificity of this pathway is determined by the E3s of which the Cullin-RING ligases (CRLs) constitute the largest subclass. CRLs are multi-subunit complexes where the enzymatic core Rbx1/Roc1, and substrate recognition modules each assemble onto the C-and N-terminus of a Cullin (Cul1, Cul2, Cul3, Cul4A, Cul4B, Cul5 and Cul7) (6) (7) (8) (9) (10) . The most well-characterized CRL is the SCF Ub ligase, comprised of Cul1, Roc1, an F-box family protein and Skp1. The F-box protein, that recruits the substrate, binds to the adaptor protein Skp1, which in turn binds onto Cul1 (11) (12) (13) (14) . In Cul3-based CRLs, instead of F-box proteins, BTB (Bric-à-brac,
Tramtrack and Broad complex)/POZ (poxviruses and zinc finger) family proteins are employed as the substrate adaptor (15) (16) (17) (18) . There are more than 180 BTB proteins encoded in the human genome (19) , and some of them have been related to substrate-targeting in Cul3 complexes. BTB proteins bind to Cul3 through the BTB domain and the adjacent '3-box (Cul3-interactin box)'
region, an element involved in facilitating this interaction (20) . Whilst interacting with Cul3, BTB proteins recruit substrates with their additional protein-protein interaction domain, such as the Kelch and MATH domains.
Of the BTBs involved in ubiquitination processes, the BTB-Kelch protein Keap1 is the best characterized. By regulating the turnover of the transcription factor Nrf2, Keap1 has an important role in the cellular defense mechanism for oxidative and xenobiotic stresses (21, 22 Antibodies-The following antibodies were used for immunoblot analyses: anti-FLAG monoclonal were transfected with FLAG-KLHL7 and HA-Ub, and treated with the proteasome inhibitor MG132 prior to immunoprecipitation. Immunoblot analyses with anti-HA antibody showed that ubiquitinated proteins interact with FLAG-KLHL7, and its amount increased drastically with proteasome inhibition ( Fig. 2A) . These data suggest that the ubiquitinated proteins that These results suggest that the increase of Ub moiety associated with KLHL7 upon proteasome inhibition is mostly due to the accumulation of poly-ubiquitinated authentic substrates.
We next examined the ligase activity of Cul3-KLHL7, in a substrate-independent in vitro ubiquitination assay (33, 34 and Ub in buffers with or without ATP (Fig. 2C ).
The amount of poly-Ub chain increased in a time dependent manner, indicating that Cul3-KLHL7 has E3 ligase activity.
Ub positive KLHL7 puncta increase with proteasome inhibition. KLHL7 and Cul3 co-localized in punctate structures in the cytoplasm (Fig. 1D ). KLHL7 also interacted with Ub, which increased with proteasome inhibition ( Fig. 2A) . Therefore we next sought to find out 3B ). As the BACK domain is necessary for the interaction with Cul3 but not for KLHL7 dimerization (Fig. 1B, C, E) , we examined if these mutants interact with Cul3 in HCT116 cells.
KLHL7 S150N could still interact with Cul3 ( Fig.   5A lane 4) , whereas the A153V and A153T mutants could not ( Fig. 5A lanes 2 and3 ). We also investigated the sub-cellular localization of these missense mutations and their co-localization with Cul3. Immunocytochemical analyses in HeLa cells showed that KLHL7 S150N has similar sub-cellular localization with wild-type KLHL7, and co-localizes with Cul3 (Supplemental Fig. 4 top). On the contrary, the sub-cellular localization of A153V and A153T was more peripheral than that of wild-type KLHL7, and co-localization with Cul3 was not as prominent ( Fig. 1D, Fig. 5B , Supplemental Fig. 4 bottom) . Taken together, these data suggest that A153 mutations in KLHL7 attenuate its interaction and co-localization with Cul3.
We next examined if the mutation in the A153 position affects the dimerization ability of KLHL7 by using the A153V mutant, as the BACK domain was important for efficient dimerization (Fig.  1E) . We expressed FLAG-KLHL7 wild-type or A153V with HA-KLHL7 wild-type or A153V in HCT116 cells and immunoprecipitated the cell lysates with anti-FLAG antibody. KLHL7 A153V was able to form both a homo dimer, and a hetero dimer with wild-type KLHL7 (Fig. 5C ). The S150N and A153T mutants could also bind to wild-type KLHL7 (Supplemental Fig. 5A ). These data suggest that none of the adRP causative mutations interfere with KLHL7 dimerization.
Immunocytochemical analyses showed that when both wild-type KLHL7 and A153V were expressed in HeLa cells, co-localization was observed in perinuclear punctate structures, resembling the sub-cellular localization of wild-type KLHL7 (Fig. 5D ). These data indicate that the sub-cellular localization of KLHL7 A153V seems to be restored to that of wild-type KLHL7, by forming a hetero dimer.
KLHL7 A153V does not inhibit Cul3-wild-type KLHL7 interaction. As KLHL7 A153V associates with wild-type KLHL7 but not directly with Cul3, we next examined the possibility that the hetero dimerization of KLHL7 A153V with wild-type KLHL7 inhibits the formation of Cul3-KLHL7 complex. To examine this, we co-expressed KLHL7 A153V with wild-type KLHL7 and investigated the amount of Cul3 that co-immunoprecipitate with wild-type KLHL7 (Fig.  6A ). Contrary to our expectations, the co-immunoprecipitation of Cul3 did not decrease even when KLHL7 A153V was co-expressed ( Fig.   6A. FLAG IP lanes 2 and 3) . Moreover, a slight amount of Cul3 could be co-immunoprecipitated by KLHL7 A153V when the wild-type KLHL7 is co-expressed (Fig. 6A HA IP lanes 1 and 3) .
Similarly, A153T was also able to associate with ( Fig. 6B) . These data indicate that the A153V mutant decreases the E3 activity of Cul3-KLHL7. (Fig 6C right) . The sub-cellular localization of A153V and A153T mutants differed from that of wild-type, suggesting that Cul3-binding and subsequent ubiquitination of the substrate may regulate the localization of KLHL7.
DISCUSSION
Consistent with this notion, none of the deletion mutants formed such punctate structures (Supplemental Fig. 1 ), including the ΔKelch mutant that associates with Cul3.
Although KLHL7 A153V and A153T did not interact with Cul3, co-expression of wild-type KLHL7 enabled the mutants to associate with Cul3. Furthermore, the localization of KLHL7 A153V returned to normal appearance with the co-expression of wild-type KLHL7.
These results suggest that the mutants can be by the proteasome and autophagic pathways (38) .
In our study, K48-linked poly-Ub positive KLHL7 puncta, increased with proteasome inhibition, suggesting that proteins ubiquitinated by Cul3-KLHL7 are degraded by the proteasome. On the other hand, the puncta did not increase with NH 4 Cl treatment ( Fig. 4 ) nor co-localize with the autophagosome marker LC3 ( Supplementary Fig.   2 ) and the lysosome marker LAMP1 (data not shown), making it unlikely that these puncta are processed by the lysosomal pathways.
RP is a heterogeneous disease, which is caused by defects in different biochemical cascades (28, 29 
